A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
Launched by VERTEX PHARMACEUTICALS INCORPORATED · Jan 17, 2024
Trial Information
Current as of March 08, 2025
Completed
Keywords
ClinConnect Summary
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- • A total body weight of more than (\>) 50 kg
- • Nonsmoker or ex-smoker for at least 3 months before the first study drug dose
- Key Exclusion Criteria:
- • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- • Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
- • Other protocol defined Inclusion/Exclusion criteria may apply.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0